Strategies Targeting cAMP Signaling in the Treatment of Polycystic Kidney Disease

被引:208
作者
Torres, Vicente E. [1 ]
Harris, Peter C. [1 ]
机构
[1] Mayo Clin, Div Nephrol & Hypertens, Rochester, MN 55905 USA
来源
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | 2014年 / 25卷 / 01期
关键词
PROTEIN-KINASE-A; LAMININ-BINDING INTEGRINS; LONG-ACTING SOMATOSTATIN; CYST EPITHELIAL-CELLS; SMOOTH-MUSCLE-CELLS; CYCLIC-AMP; RECEPTOR SUBTYPES; LIVER-DISEASE; IN-VITRO; PKD1; HAPLOINSUFFICIENCY;
D O I
10.1681/ASN.2013040398
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Polycystic kidney disease (PKD) is a leading cause of ESRD worldwide. In PKD, excessive cell proliferation and fluid secretion, pathogenic interactions of mutated epithelial cells with an abnormal extracellular matrix and alternatively activated interstitial macrophages, and the disruption of mechanisms controlling tubular diameter contribute to cyst formation. Studies with animal models suggest that several diverse pathophysiologic mechanisms, including dysregulation of intracellular calcium levels and cAMP signaling, mediate these cystogenic mechanisms. This article reviews the evidence implicating calcium and cAMP as central players in a network of signaling pathways underlying the pathogenesis of PKD and considers the therapeutic relevance of treatment strategies targeting cAMP signaling.
引用
收藏
页码:18 / 32
页数:15
相关论文
共 171 条
[11]   Expression of somatostatin in the adult and developing mouse kidney [J].
Bates, CM ;
Kegg, H ;
Grady, S .
KIDNEY INTERNATIONAL, 2004, 66 (05) :1785-1793
[12]   Expression of somatostatin receptors 1 and 2 in the adult mouse kidney [J].
Bates, CM ;
Kegg, H ;
Grady, S .
REGULATORY PEPTIDES, 2004, 119 (1-2) :11-20
[13]   Expression of somatostatin and somatostatin receptor subtypes 1-5 in human normal and diseased kidney [J].
Bhandari, Sunil ;
Watson, Neil ;
Long, Ervine ;
Sharpe, Steve ;
Zhong, Wenwen ;
Xu, Shang-Zhong ;
Atkin, Stephen L. .
JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY, 2008, 56 (08) :733-743
[14]  
Blazer-Yost BL, 2010, PPAR RES, V2010, DOI [10.1155/2010/785369, 10.1155/2010/274376]
[15]   Biochemical characterization of bona fide polycystin-1 in vitro and in vivo [J].
Boletta, A ;
Qian, F ;
Onuchic, LF ;
Bragonzi, A ;
Cortese, M ;
Deen, PM ;
Courtoy, PJ ;
Soria, MR ;
Devuyst, O ;
Monaco, L ;
Germino, GG .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2001, 38 (06) :1421-1429
[16]   The Raf kinase inhibitor PLX5568 slows cyst proliferation in rat polycystic kidney disease but promotes renal and hepatic fibrosis [J].
Buchholz, Bjoern ;
Klanke, Bernd ;
Schley, Gunnar ;
Bollag, Gideon ;
Tsai, James ;
Kroening, Sven ;
Yoshihara, Daisuke ;
Wallace, Darren P. ;
Kraenzlin, Bettina ;
Gretz, Norbert ;
Hirth, Peter ;
Eckardt, Kai-Uwe ;
Bernhardt, Wanja M. .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2011, 26 (11) :3458-3465
[17]   Axial heterogeneity of vasopressin-receptor subtypes along the human and mouse collecting duct [J].
Carmosino, Monica ;
Brooks, Heddwen L. ;
Cai, Qi ;
Davis, Linda S. ;
Opalenik, Susan ;
Hao, Chuanming ;
Breyer, Matthew D. .
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 2007, 292 (01) :F351-F360
[18]   Reducing Polycystic Liver Volume in ADPKD: Effects of Somatostatin Analogue Octreotide [J].
Caroli, Anna ;
Antiga, Luca ;
Cafaro, Mariateresa ;
Fasolini, Giorgio ;
Remuzzi, Andrea ;
Remuzzi, Giuseppe ;
Ruggenenti, Piero .
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2010, 5 (05) :783-789
[19]   Planar cell polarity in kidney development and disease [J].
Carroll, Thomas J. ;
Das, Amrita .
ORGANOGENESIS, 2011, 7 (03) :180-190
[20]  
Chapman AB, 2005, J AM SOC NEPHROL, V16, p68A